Rasmus Holm-Jorgensen
Finanzdirektor/CFO bei ACRIVON THERAPEUTICS, INC.
Vermögen: 210 432 $ am 31.05.2024
Aktive Positionen von Rasmus Holm-Jorgensen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.04.2022 | - |
Karriereverlauf von Rasmus Holm-Jorgensen
Ehemalige bekannte Positionen von Rasmus Holm-Jorgensen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Gründer | 01.07.2015 | 01.04.2022 |
| Corporate Officer/Principal | 01.07.2015 | 01.04.2022 | |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01.01.2011 | 01.01.2015 |
Ausbildung von Rasmus Holm-Jorgensen
| University of Copenhagen | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| Dänemark | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Founder | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
- Börse
- Insiders
- Rasmus Holm-Jorgensen
- Erfahrung